SI
MRVI icon

Symmetry Investments’s Maravai LifeSciences MRVI Stock Holding History

Symmetry Investments’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,000
Closed -$81.8K – 189
2024
Q4 		$81.8K Hold
15,000
– – ﹤0.01% 158
2024
Q3 		$125K Buy
+15,000
New +$130K 0.02% 116

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Symmetry Investments's MRVI Position: Q1 2026 in Review

Symmetry Investments increased its Maravai LifeSciences (MRVI) stake by 39% in Q1 2026, buying an estimated $341K and bringing the position to 359,561 shares worth $1.02M. The position accounts for 0.11% of the portfolio, ranked #92.

Symmetry Investments first reported a position in MRVI in Q2 2024 and has held it in 8 quarters since. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Symmetry Investments held 359,561 shares of Maravai LifeSciences worth $1.02M as of Q1 2026.
  • Symmetry Investments bought 100,528 Maravai LifeSciences shares in Q1 2026, an estimated $341K.
  • Maravai LifeSciences made up 0.11% of Symmetry Investments's portfolio in Q1 2026, its #92 holding.
  • Symmetry Investments first reported a position in Maravai LifeSciences in Q2 2024 and has held it in 8 quarters since.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Symmetry Investments's 13F filing for Q1 2026, filed 15 May 2026.